Biotech | March 09, 2022
Alvotech settles with AbbVie to secure US rights to Humira biosimilar
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
This supply agreement provides material for the company’s planned 30-patient pilot study, and later for its planned U.S. pivotal study in spine fusion patients
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Subscribe To Our Newsletter & Stay Updated
